NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
Clinical Trials
10 trialsNCT05489211 2025-07-11
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
Phase 2 Recruiting
NCT04034251 2025-02-03
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00354601 2017-08-30
Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer
Wake Forest University Health Sciences
Phase 2 Terminated
NCT00039442 2017-08-24
Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer
GOG Foundation
Phase 2 Completed
NCT00403429 2016-01-14
MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer
National Cancer Institute, Naples
Phase 2 Completed
NCT00004012 2013-06-24
Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00016926 2013-05-27
Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
GOG Foundation
Phase 2 Completed
NCT00006812 2013-04-11
Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
GOG Foundation
Phase 2 Terminated
NCT00257348 2013-02-08
Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer
University of California, Irvine
Phase 2 Completed